Forums » News and Announcements

Identification of the growth-hormone-releasing peptide-2

    • 1085 posts
    September 30, 2019 11:02 AM EDT
    Black market products of a pharmaceutical nature and nutritional
    supplements have received substantial and increasing attention because
    of potential performance enhancement in elite and non-professional
    sports. In addition, improved general health is claimed for
    non-competing individuals. The risks and foreseeable dangers of the
    uncontrolled use of highly potent and non-approved pharmaceutical
    compounds in healthy individuals are of considerable concern. In the
    present case report, the emerging drug candidate GHRP-2 with verified
    growth-hormone-releasing properties was identified and quantified in
    tablets offered as an over-the-counter nutritional supplement. GHRP-2 powder,GHRP 2 powder
    The
    impact of this orally active peptide on the hGH/IGF-axis has been
    established for several years and its illicit use in elite sports has
    been assumed. As a releasing factor for hGH, GHRP-2 belongs to the list
    of substances prohibited by the World Anti-Doping Agency (WADA).
    Unfortunately, to date there is no routinely performed assay for the
    determination of these peptides potentially occurring in biological
    fluids of competing athletes, but the present data will facilitate the
    implementation by providing principle analytical information on liquid
    chromatographic and mass spectrometric behaviour.
    Qualitative
    identification of the target analyte after extraction from the tablet
    matrix was performed by high resolution/high accuracy mass spectrometry
    after liquid chromatographic separation under consideration of the
    accurate masses and the ratios of the protonated molecules and their
    fragment ions derived from their collisionally induced dissociation.
    Quantitative results were obtained by means of liquid chromatography
    coupled to a triple quadrupole mass spectrometer and linear regression
    using an external calibration curve (with GHRP-2 reference compound)
    adjusted via internal standard (Hexarelin). Hereby, the content of
    GHRP-2 was determined with approximately 50 µg per tablet.